Current
—
5-Year Average
—
All-Time High
—
All-Time Low
—
P/FCF Ratio daily chart for SELLAS Life Sciences Group (SLS)
Jun 14, 2021 – Jun 12, 2026 · 1,256 trading days
P/FCF ratio is not shown for periods when TTM free cash flow was negative.
Historical P/FCF Ratio for SELLAS Life Sciences Group (SLS) from 2007 to 2025
| 2025 | $577.20M | −$28.39M | — | — | |
| 2024 | $76.95M | −$35.40M | — | — | |
| 2023 | $32.65M | −$39.91M | — | — | |
| 2022 | $49.05M | −$28.31M | — | — | |
| 2021 | $87.88M | −$26.02M | — | — | |
| 2020 | $60.33M | −$10.42M | — | — | |
| 2019 | $20.71M | −$17.64M | — | — | |
| 2018 | $26.81M | −$30.42M | — | — | |
| 2017 | $41.73M | −$10.99M | — | — | |
| 2016 | $72.75M | −$44.91M | — | — | |
| 2015 | $2.14B | −$48.31M | — | — | |
| 2014 | $1.67B | −$48.40M | — | — | |
| 2013 | $5.19B | −$44.76M | — | — | |
| 2012 | $1.14B | −$20.96M | — | — | |
| 2011 | $202.79M | −$14.67M | — | — | |
| 2010 | $575.39M | −$10.36M | — | — | |
| 2009 | $755.56M | −$11.77M | — | — | |
| 2008 | $711.04M | −$9.60M | — | — | |
| 2007 | $1.19B | −$6.28M | — | — |
- 2025—
- 2024—
- 2023—
- 2022—
- 2021—
- 2020—
- 2019—
- 2018—
- 2017—
- 2016—
- 2015—
- 2014—
- 2013—
- 2012—
- 2011—
- 2010—
- 2009—
- 2008—
- 2007—
About P/FCF Ratio at SELLAS Life Sciences Group (SLS)
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by P/FCF ratio.
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 3.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric